Therapeutics News and Research

RSS

Novelos Therapeutics acquires Cellectar

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that it has completed its acquisition of Cellectar, Inc., a Wisconsin-based drug development company, in a stock-for-stock transaction.

12 Apr 2011

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant from the National Cancer Institute under the agency's Streamlined Non-competing Award Procedures.

11 Apr 2011

AHF praises CA Treasurer for urging AIDS drug companies to reduce medication costs

Today AIDS Healthcare Foundation praised California State Treasurer Bill Lockyer for sending letters to the CEOs of eight AIDS drug companies—Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Sciences, Merck & Co., Tibotec Therapeutics and ViiV Healthcare—urging them to reduce the price of their HIV/AIDS medications for California and its AIDS Drug Assistance Program.

11 Apr 2011

Scientists develop new approach to accelerate evolution of biomolecules in lab

Scientists at Harvard University have harnessed the prowess of fast-replicating bacterial viruses, also known as phages, to accelerate the evolution of biomolecules in the laboratory.

11 Apr 2011

Takeda, Heptares collaborate to develop new drugs against CNS disorders

Heptares Therapeutics and Takeda Pharmaceutical Company today announced the formation of a two-year drug discovery collaboration focused on a single G-protein coupled receptor that plays an important role in the pathology of central nervous system disorders.

11 Apr 2011

Experimental Biology 2011 to be held April 9-13 in Washington, D.C.

The meeting Experimental Biology 2011 (EB 2011) begins April 9 and runs through April 13 at the Walter E. Washington Convention Center in Washington, D.C.

8 Apr 2011

Precision launches new tumor profiling product

Precision Therapeutics, Inc. announced that the launch of a new product line, BioSpeciFx, will help further the personalization of cancer treatments.

8 Apr 2011

ASBMB honors UMMS professor with 2011 William C. Rose Award

The American Society for Biochemistry and Molecular Biology has named Melissa J. Moore, a professor at the University of Massachusetts Medical School, the winner of the society's 2011 William C. Rose Award.

8 Apr 2011

CFFT, Vertex collaborate to develop new medicines for cystic fibrosis

Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics, Inc. today announced they will collaborate on the continued discovery and development of new medicines known as correctors that aim to treat the underlying cause of cystic fibrosis in people with the most common form of the disease.

8 Apr 2011

FDA issues Approvable Letter for Oceana's Solesta in treatment for bowel incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter for Solesta® as a treatment for fecal (bowel) incontinence.

7 Apr 2011

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

AlCana Technologies, Inc., The University of British Columbia, and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Alnylam has elected to extend the companies' RNAi therapeutics research collaboration for a third year.

7 Apr 2011

DSP, BBI sign license agreement for BBI608

Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc., today announced that they have signed a Product Option License Agreement for BBI608 for all oncology indications in Japan and exclusive right of negotiation for BBI608 for the United States and Canada.

7 Apr 2011

Alnylam defends against Tekmira complaint, files answer and counterclaim

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, has filed an answer and counterclaim to a complaint filed by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court.

7 Apr 2011

Breast cancer symposium to discuss on latest advances in research and treatment

The latest advances in both breast cancer treatment and research - including innovations in diagnostic, surgical, chemotherapy and radiation approaches - will be discussed Friday, April 8, 2011, at a breast cancer symposium at the Kimmel Cancer Center at Jefferson in Philadelphia.

7 Apr 2011

USPTO issues notice of allowance to Mirna's mir34a patent application

Mirna Therapeutics, Inc. announced today that the United States Patent and Trademark Office has allowed patent claims related to the therapeutic application of the potent tumor suppressor microRNA, mir34a.

7 Apr 2011

Hartwell honors UCSD scientists with Individual Biomedical Research Award

Three scientists at the University of California, San Diego School of Medicine are among this year's 12 winners of Hartwell Individual Biomedical Research Awards, honoring researchers whose work advances children's health.

7 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

Study: New cancer drug shrinks tumors in mouse model with few side effects

A study led by researchers at the University of Michigan Comprehensive Cancer Center showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.

7 Apr 2011

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced that it has successfully completed two Phase 1a clinical studies for AVL-292, its orally-available, selective inhibitor of Bruton's tyrosine kinase (Btk).

6 Apr 2011

Ascletis raises $100 million in committed financing

Ascletis, Inc., a U.S.-China specialty life sciences venture focused on cancer and infectious disease therapeutics, today announced the company's formation and completion of a Series A private equity financing. Ascletis has raised US$100 million in committed financing including a first tranche of US$50 million. The investors, led by Hangzhou Binjiang Investment Holding Co., Ltd., included private entrepreneurs from China and other countries including the United States.

6 Apr 2011